SCHEDULE 13G/A: Adjuvant Capital Entities Report 7.9% Beneficial Ownership in AN2 Therapeutics
Beneficial Ownership Report
Adjuvant Global Health Technology Fund, L.P. and its related entities have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 7.9% of AN2 Therapeutics, Inc.'s common stock as of December 31, 2024.
Summary
- Adjuvant Global Health Technology Fund, L.P. (AGHT Fund) beneficially owns 1,995,958 shares of AN2 Therapeutics, Inc. common stock, representing 6.7% of the class.
- Adjuvant Global Health Technology Fund DE, L.P. (AGHT Fund DE) beneficially owns 377,542 shares of AN2 Therapeutics, Inc. common stock, representing 1.3% of the class.
- Adjuvant Capital GP, L.P. (AC GP) and Adjuvant Capital Management, L.L.C. (AC Management) each beneficially own an aggregate of 2,373,500 shares, representing 7.9% of AN2 Therapeutics, Inc.'s common stock.
- AC GP serves as the sole general partner for both AGHT Fund and AGHT Fund DE.
- AC Management is the sole general partner of AC GP, establishing a control relationship over the beneficially owned shares.
- The filing is an Amendment No. 2 to Schedule 13G, indicating an update to previously reported ownership information.
- The beneficial ownership is reported as of December 31, 2024, with the filing dated February 28, 2025.
Sentiment
Score: 5
Explanation: The document is a standard beneficial ownership disclosure (Schedule 13G) and does not contain information that would inherently convey positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
NA
Industry Context
This Schedule 13G filing is a routine disclosure of beneficial ownership by an institutional investor in a publicly traded company. It does not provide specific industry context or trends beyond the fact of the investment itself.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership in AN2 Therapeutics, Inc.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (beneficial ownership snapshot date). |
| 02/28/2025 | Date of filing and signature date for the Schedule 13G Amendment No. 2. |
Keywords
AN2 Therapeutics, Adjuvant Global Health Technology Fund, Adjuvant Capital, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.